Correction to: Infect Dis Ther https://doi.org/10.1007/s40121-022-00734-5


Data errors have been found in the original article. These errors are highlighted here and the original article has been corrected.

The two main errors were:

  1. 1.

    The AR-related regimen discontinuation:

    • The misclassification of one AR-related regimen discontinuation in DTG/ABC/3TC arm (from skin manifestation to renal toxicity).

    • One episode of dyslipidemia-related regimen discontinuation in DTG/ABC/3TC arm was mistakenly labeled in B/F/TAF arm.

    • There was only one episode of skin manifestation in B/F/TAF, not two episodes.

    • There is also an error in the statistical analysis for categorical variables in Table 3.

  2. 2.

    The subgroup analysis of the determinant of regimen discontinuation is the determinant limited to AR or virological failure-related regimen discontinuation, instead of being limited to AR-related regimen discontinuation.

All errors are corrected below (in bold).

Table 3 Between-regimen differences in the categories of virological failure and regimen discontinuation
Full size table

Before

After

Correction 1

1. The AR-related regimen discontinuation:

The misclassification of one AR-related regimen discontinuation in DTG/ABC/3TC arm (from skin manifestation to renal toxicity)

One episode of dyslipidemia-related regimen discontinuation in DTG/ABC/3TC arm was mistakenly labeled in B/F/TAF arm.

There was only one episode of skin manifestation in B/F/TAF, not two episodes.

There is also an error in the statistical analysis for categorical variables in Table 3.

In the method, under the subtitle of working definition

Reasons that were classified as other included pregnancy, lifestyle and diet considerations, drug–drug interactions, or provider choice. ARs were further categorized as central nervous system toxicity (dizziness, headache, insomnia, abnormal dreams, or vertigo), skin manifestations (pruritus, rash, or hypersensitivity reaction), gastrointestinal or hepatic toxicity (gastrointestinal intolerability, nausea, vomiting, jaundice, or hepatitis), or renal toxicity (declining estimated glomerular filtration rate or proteinuria)

Reasons that were classified as other included pregnancy, lifestyle and diet considerations, drug–drug interactions, or provider choice. ARs were further categorized as central nervous system toxicity (dizziness, headache, insomnia, abnormal dreams, or vertigo), skin manifestations (pruritus, rash, or hypersensitivity reaction), gastrointestinal or hepatic toxicity (gastrointestinal intolerability, nausea, vomiting, jaundice, or hepatitis), or renal toxicity (declining estimated glomerular filtration rate, electrolyte imbalance, or proteinuria)

In the result, under the subtitle of Time to regimen discontinuation

The most common reason for discontinuation in both groups was ARs (61.9% [13/21] in the DTG/ABC/3TC group and 50% [2/4] in the B/F/TAF group, P = 0.877), and skin manifestations were the most common ARs in both groups (69.2% in the DTG/ABC/3TC group and 100% in the B/F/TAF group, P = 0.485).

The most common reason for discontinuation in both groups was ARs (61.9% [13/21] in the DTG/ABC/3TC group and 50% [2/4] in the B/F/TAF group, P = 0.877), and skin manifestations were the most common ARs in both groups (61.5% in the DTG/ABC/3TC group and 50% in the B/F/TAF group, P = 0.756).

In the discussion, the 5th paragraph

In the present study, 9.09% of individuals in the DTG/ABC/3TC group experienced regimen discontinuation due to AR, of which skin manifestations were the most common (69.2%).

In the present study, 8.08% of individuals in the DTG/ABC/3TC group experienced regimen discontinuation due to AR, of which skin manifestations were the most common (61.5%).

In the discussion, the 6th paragraph

In this retrospective cohort study, it was not possible to confirm the incidence of AR-related regimen discontinuation due to HSR (the term “HSR” was recorded in the electronic medical records for two patients in the DTG/ABC/3TC group who discontinued treatment).

In this retrospective cohort study, it was not possible to confirm the incidence of AR-related regimen discontinuation due to HSR (the term “HSR” was suspected in the electronic medical records for two patients in the DTG/ABC/3TC group who discontinued treatment).

Correction 2

2. The subgroup analysis of the determinant of regimen discontinuation is the determinant limited to AR or virological failure-related regimen discontinuation, instead of being limited to AR-related regimen discontinuation.

In the abstract, under the subtitle of result

The main reason for discontinuation in both groups was ARs (61.9% in the DTG/ABC/3TC and 50% in the B/F/TAF, P = 0.877), of which skin manifestations were the most common in both groups (69.2% in the DTG/ABC/3TC and 100% in the B/F/TAF, P = 0.485). DTG/ABC/3TC, same-day ART prescription, and AOI were risk factors for AR-related regimen discontinuation.

The main reason for discontinuation in both groups was ARs (61.9% in the DTG/ABC/3TC and 50% in the B/F/TAF, P = 0.877), of which skin manifestations were the most common in both groups (61.5% in the DTG/ABC/3TC group and 50% in the B/F/TAF group, P = 0.756). DTG/ABC/3TC, same-day ART prescription, and AOI were risk factors for AR or virological failure-related regimen discontinuation.

In the abstract, under the subtitle of conclusion

In the real world, the risk of regimen discontinuation was higher in PLWAH on coformulated DTG/ABC/3TC than in those on B/F/TAF, with no difference in viral suppression or virological failure. Given the findings concerning the effect of same-day ART prescription and AOIs on AR-related regimen discontinuation, individualized approaches to PLWAH are necessary.

In the real world, the risk of regimen discontinuation was higher in PLWAH on coformulated DTG/ABC/3TC than in those on B/F/TAF, with no difference in viral suppression or virological failure. Given the findings concerning the effect of same-day ART prescription and AOIs on AR or virological failure-related regimen discontinuation, individualized approaches to PLWAH are necessary.

In the result, under the subtitle of Time to regimen discontinuation

When reasons for regimen discontinuation were limited to ARs, same-day prescription (aHR = 11.15, 95% CI: 3.03–40.98; P < 0.001) and AOI (aHR = 4.49, 95% CI: 1.23–16.37; P < 0.023) were associated with a significantly higher risk of regimen discontinuation.

When reasons for regimen discontinuation were limited to ARs or virological failure, same-day prescription (aHR = 11.15, 95% CI: 3.03–40.98; P < 0.001) and AOI (aHR = 4.49, 95% CI: 1.23–16.37; P < 0.023) were associated with a significantly higher risk of regimen discontinuation.

In the discussion, the 8th paragraph

The incidence of AR-related regimen discontinuation was also associated with AOIs and same-day ART, possibly due to drug–drug interactions between non-cART regimens for AOIs and cART or toxicities attributable to AOI treatment [15, 16, 40]

The incidence of AR or virological failure-related regimen discontinuation was also associated with AOIs and same-day ART, possibly due to drug–drug interactions between non-cART regimens for AOIs and cART or toxicities attributable to AOI treatment [15, 16, 40]

In the conclusion

Although the regimens do not differ in time to viral suppression or virological failure, B/F/TAF is preferred over DTG/ABC/3TC for initial therapy in PLWAH because B/F/TAF is more tolerable. Whether skin manifestations contribute to AR-related discontinuation of DTG/ABC/3TC requires further prospective investigation. Further, the strong associations of same-day ART prescription and AOIs with AR-related regimen discontinuation may indicate the need for individualized approaches to treatment-naïve PLWAH in the era of rapid ART.

Although the regimens do not differ in time to viral suppression or virological failure, B/F/TAF is preferred over DTG/ABC/3TC for initial therapy in PLWAH because B/F/TAF is more tolerable. Whether skin manifestations contribute to AR-related discontinuation of DTG/ABC/3TC requires further prospective investigation. Further, the strong associations of same-day ART prescription and AOIs with AR or virological failure-related regimen discontinuation may indicate the need for individualized approaches to treatment-naïve PLWAH in the era of rapid ART.